This was highlighted in an experimental study performed on GLP-1-treated HL-1 cardiomyocytes, in which GLP1 increased calcium transients and sarcoplasmic reticular calcium contents by regulating the expression of calcium handling proteins, leading to a reduced calcium leak and thus preventing AF development [34]
[2] [3] However, in April 2025, Pfizer announced it would abandon further development of danuglipron due to unpredictable liver toxicity
doi: 10.1016/j.jprot.2021.104427
doi:10.1111/ijd.17535 Al-Saimaa A, Farahat M, El-Garhy L et al
Long-term, unmonitored use might also lead to lowered zinc levels
This evening is designed to give guests a clear, practical understanding of how GLP-1 medications work, what results may be possible, what risks or side effects to consider, and what type of medical guidance is important throughout treatment